Eckert & Ziegler boosts early phase offering with Vitalea Science takeover
The deal - terms of which were not disclosed - adds Vitalea’s range of accelerator mass spectrometry (AMS) technologies and preclinical and early phase clinical services to Eckert & Ziegler’s offering.
Frank Yeager, president and CEO of Eckert & Ziegler Isotope Products, said: "Vitalea is a unique company with a very unique capability built around the BioMICADAS device, which is the state-of-the-art in AMS technology. We believe that this capability will both allow Eckert & Ziegler to add value to our existing customer base and expand our area of expertise in new markets."
This was echoed by Bob Bethem, president and CEO at Vitalea Science, who said that: “The acquisition of Vitalea Science by Eckert & Ziegler helps to provide the commercial strength of EZAG to the technical prowess of Vitalea."
